Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID: NCT00691405

Public ClinicalTrials.gov record NCT00691405. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Randomized, Multicenter, Two-part Parallel-group, Dose-ranging Study of Twice-daily and Once-daily (R,R) Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A dose ranging study to evaluate the safety, tolerability and efficacy of arformoterol (given once or twice a day) in subjects with COPD.

Study identification

NCT ID
NCT00691405
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Enrollment
215 participants

Conditions and interventions

Eligibility (public fields only)

Age range
35 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2003
Primary completion
Apr 30, 2004
Completion
Apr 30, 2004
Last update posted
Feb 21, 2012

2003 – 2004

United States locations

U.S. sites
31
U.S. states
14
U.S. cities
31
Facility City State ZIP Site status
Not listed Encinitas California
Not listed Long Beach California
Not listed Brandon Florida
Not listed Cleawater Florida
Not listed Fort Lauderdale Florida
Not listed Jacksonville Florida
Not listed Port Orange Florida
Not listed West Palm Beach Florida
Not listed Austell Georgia
Not listed Topeka Kansas
Not listed Marrero Louisiana
Not listed New Orleans Louisiana
Not listed Opelousas Louisiana
Not listed McCook Nebraska
Not listed Princeton New Jersey
Not listed Hickory North Carolina
Not listed Statesville North Carolina
Not listed Winston-Salem North Carolina
Not listed Columbus Ohio
Not listed Eugene Oregon
Not listed Medford Oregon
Not listed Pittsburgh Pennsylvania
Not listed Charleston South Carolina
Not listed Columbia South Carolina
Not listed Simpsonville South Carolina
Not listed Spartanburg South Carolina
Not listed Austin Texas
Not listed San Antonio Texas
Not listed Renton Washington
Not listed Spokane Washington
Not listed Tacoma Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00691405, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 21, 2012 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00691405 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →